Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
Status:
Completed
Trial end date:
2022-05-24
Target enrollment:
Participant gender:
Summary
Primary objective:
To evaluate the plasma and urine PK of givinostat following multiple oral doses of
givinostat.
Secondary objective:
To assess the safety and tolerability multiple oral doses of givinostat.